The broad, long-range objectives are to develop state-of art mass spectrometric (MS) methodologies for: (i) the specific, sensitive, and rapid monitoring of drug levels in serum and urine samples from patients on ACTG protocols and (ii) the investigation of the effects of disease states and advanced age on the metabolism of drugs used in ACTG protocols. There will be five specific aims: (1) Investigate the utility of electrospray (at atmospheric pressure) ionization, in the single ion monitoring mode, as a """"""""universal"""""""" ionization technique for the quantification of low molecular weight, underivatized drugs and their metabolites using: (i) direct injection (without chromatographic separation) of serum or urine ultrafiltrates, or (ii) effluents from single or switched multiple chromatographic columns capable of handling direct serum or urine injections; (2) Develop quantification techniques of oligonucleotides, interferons, and other high molecular weight drugs of interest in serum and urine using electrospray ionization; (3) Develop MS """"""""referee"""""""" techniques for drugs commonly used in existing ACTG protocols, employing combined liquid or gas chromatography-MS techniques with fast ion bombardment, thermospray, electrospray, or chemical ionization; (4) Explore the use of multiple ion monitoring techniques for the simultaneous quantification of drugs and their metabolites in combination chemotherapy; (5) Use MS or tandem MS (MS/MS) techniques of high specificity to identify in serum and urine samples from patients with renal or hepatic failure, or of advanced age: (i) endogenous constituents the concentration of which drastically changes chromatographic profiles with respect to patients without these conditions, thereby interfering with the chromatographic analysis of drug or metabolite levels; (ii) the effects of these conditions on drug metabolism, i.e., appearance of additional metabolites and/or excessive changes in metabolite concentrations. These new methodologies will be of immediate and direct benefit to patients on ACTG protocols because they will lead to dose and regimen adjustments to increase efficacy and reduce toxicity.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mount Sinai School of Medicine
New York
United States
Zip Code
Nasti, Tahseen H; Cochran, J Barry; Tsuruta, Yuko et al. (2016) A murine model for the development of melanocytic nevi and their progression to melanoma. Mol Carcinog 55:646-58
Zhao, Yu; Navia, Bradford A; Marra, Christina M et al. (2010) Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials 11:59-67
Smith, Patrick F; Robbins, Gregory K; Shafer, Robert W et al. (2005) Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrob Agents Chemother 49:3558-61
Gilpin, Adele M Kaplan; Holbrook, Janet T; Jabs, Douglas A et al. (2003) Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial. Control Clin Trials 24:92-8
Holbrook, Janet T; Jabs, Douglas A; Weinberg, David V et al. (2003) Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol 121:99-107
Jabs, Douglas A; Gilpin, Adele M Kaplan; Min, Yuan-I et al. (2002) HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. AIDS 16:877-87
Martin, B K; Kaplan Gilpin, A M; Jabs, D A et al. (2001) Reliability, validity, and responsiveness of general and disease-specific quality of life measures in a clinical trial for cytomegalovirus retinitis. J Clin Epidemiol 54:376-86
Holbrook, J T; Meinert, C L; Jabs, D A et al. (2001) Patient notification and follow-up after suspension of treatment protocols. experience from four clinical trials of treatments for AIDS-related CMV retinitis. Control Clin Trials 22:62-8
Holbrook, J T; Meinert, C L; Van Natta, M L et al. (2001) Photographic measures of cytomegalovirus retinitis as surrogates for visual outcomes in treated patients. Arch Ophthalmol 119:554-63
Perlman, D C; El-Helou, P; Salomon, N (1999) Tuberculosis in patients with human immunodeficiency virus infection. Semin Respir Infect 14:344-52

Showing the most recent 10 out of 35 publications